Equitable Access to Biomarker Testing and Perioperative Treatment Critical for NSCLC Outcomes

Dr. Frank Weinberg, assistant professor and head of the thoracic oncology program at the University of Illinois Cancer Center, highlighted critical gaps in equitable access to advanced non-small cell lung cancer (NSCLC) treatments during a recent Institute for Value-Based Medicine event in Chicago. His insights underscore how access barriers, rather than just biological factors, significantly impact patient outcomes in lung cancer care.

Access Determines Outcomes Beyond Biology

"Lung cancer outcomes aren't determined on biology alone. They're shaped by access," Weinberg explained. "If certain communities don't get biomarker testing or can't reach the right specialists or oncologists, they're going to miss out on the best therapies for them."

The oncologist emphasized that while scientific advances in NSCLC treatment are progressing rapidly, access to these innovations isn't keeping pace across all patient populations. This disparity particularly affects biomarker testing and perioperative immunotherapy, which Weinberg described as "the new player in the field."

Evolving Treatment Landscape Presents Implementation Challenges

During panel discussions with clinicians from various health systems, Weinberg noted the practical challenges of implementing rapidly evolving treatment protocols. "Perioperative treatment and biomarker testing is changing every day with more and more targets," he observed, highlighting the need for healthcare systems to adapt quickly to incorporate new therapeutic approaches.

The conversations revealed institutional barriers that prevent optimal care delivery, particularly around biomarker testing accessibility. Weinberg stressed the importance of understanding these barriers and developing strategies to overcome them, noting that successful institutions have found ways to ensure patients receive necessary care despite systemic challenges.

Equity Strengthens Scientific Research

Beyond individual patient benefits, Weinberg argued that equitable access enhances the scientific foundation of NSCLC treatment. "Equity really ensures everyone has a fair chance at the best possible outcome. It strengthens the science actually, because by including all of a large, diverse population and participation, you're going to be able to make treatments more effective for all patients."

This perspective positions equity not as a separate consideration but as integral to advancing cancer care effectiveness across all patient populations.

Physician Advocacy and Communication Key to Solutions

Weinberg outlined a dual role for oncologists in addressing access disparities. "I think one obviously to always advocate for our patients to get the right therapy, and then also communication with our patients and that's the way that we build trust," he explained.

At the University of Illinois Cancer Center, Weinberg's team has observed that even basic communication about clinical trial options can significantly impact patient care. "We know that even that little communication on what a clinical trial even is, that small step can ensure patients understand their options, and that can make a real difference in their care."

Systemic Changes Needed for Community Practices

Addressing broader systemic issues, Weinberg called for policy changes that would enable community practices to deliver cutting-edge care more effectively. He specifically mentioned making biomarker testing more accessible in community settings and expanding clinical trial availability beyond academic medical centers.

The oncologist's observations from the Chicago event reinforced that while NSCLC treatment options continue to expand with new biomarkers and perioperative approaches, the healthcare system must simultaneously address access barriers to ensure all patients benefit from these advances.